Donald Shaffer
Head of Immuno-Oncology & Cell Therapy Sanofi
Seminars
Tuesday 9th September 2025
Designing Targeted Cytokines: Preclinical Lessons from PD-1/PD-L1- Directed IL-15 Bispecifics
1:45 pm
- SAR445710 (KD033) a trans-presented high affinity IL-15 vs SAR445877 (KD050) a cispresented reduced affinity IL-15
- Reviewing pre-clinical in vitro and in vivo pharmacology data
- Exploring broader design considerations for targeted cytokines in oncology and beyond
